Jan. 24, 2022 – With the COVID-19 pandemic heading into year three, the Food and Drug Administration (FDA) faces ongoing challenges but continues to work on four primary agency priorities, according to Nancy Bradish Myers, president of Catalyst Healthcare Consulting, who spoke at a Jan. 21 Coalition for Healthcare Communication webinar, “A New Start for […]
Read more
June 29, 2021 – In the wake of the FDA granting a controversial accelerated approval for Biogen’s aducanumab (Aduhelm) – and Biogen’s decision to set the list price for the drug for Alzheimer’s disease at $56,000 per year despite equivocal evidence of efficacy – members of Congress are introducing drug pricing legislation, calling for hearings, […]
Read more Nov. 11, 2019 – As Congress works to agree on legislation that would rein in drug prices, a bill co-sponsored by Sen. Charles Grassley (R-Iowa) and Sen. Dick Durbin (D-Ill.) – which would require that list prices be included in direct-to-consumer (DTC) television advertisements – may be close to a vote. Grassley and Durbin hoped […]
Read more
Sept. 16, 2019 – Five research studies conducted by the FDA’s Office of Prescription Drug Promotion (OPDP) – four of which examine aspects of direct-to-consumer (DTC) advertising – are complete and awaiting peer review and publication, according to OPDP’s Website. “Taken together, the OPDP studies now nearing release will make an important contribution to the […]
Read more
Aug. 13, 2018 – The FDA released final details about the study it plans to conduct on the effectiveness of drug company disclosures in professional and consumer prescription drug promotion in an Aug. 9 Federal Register notice. Specifically, the aim of the research is to “examine the effectiveness of clear and conspicuous disclosures in prescription […]
Read more May 21, 2018 – Since the Trump administration presented its proposal to lower drug pricing on May 11, both the trade and mainstream media have been discussing whether one provision – a request that the Department of Health & Human Services evaluate the inclusion of drug prices in consumer ads – really has legs. In […]
Read more
March 14, 2018 – The FDA has “prioritized a robust social and behavioral science research program” to help the agency understand “how consumers respond to prescription drug promotion,” according to FDA Commissioner Scott Gottlieb, M.D. This Office of Prescription Drug Promotion (OPDP) research “has provided key information to inform our policies related to the proper […]
Read moreDec. 28, 2015 – The supposed ill effects of direct-to-consumer (DTC) advertising are being levied without much evidence, according to a recent article by Robert Palmer, EVP, director of Digital and Video for JUICE Pharma Worldwide. The well-balanced article, “The DTC Advertising Dilemma,” posted on the JUICE blog Dec. 14, discusses the recent American Medical […]
Read moreNov. 17, 2015 — The American Medical Association (AMA) announced today that it would support an advertising ban on direct-to-consumer (DTC) advertising in an effort to make prescription drugs more affordable and address member concerns regarding “the negative impact of commercially-driven promotions and the role that marketing costs play in fueling escalating drug prices.” The […]
Read moreOct. 20, 2015 – The FDA’s announcement last week that it was accepting comments on two new studies of direct-to-consumer (DTC) television advertising for prescription drugs adds these studies to the growing pile of research the agency is accumulating to better understand consumers’ comprehension of what is being communicated through these ads. To help industry […]
Read more